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Abstract
Background:  Adiponectin is a major adipocyte-derived protein with insulin-sensitizing, anti-
inflammatory and anti-atherogenic properties. Adiponectin levels correlate inversely with renal
function and higher levels are predictive of lower cardiovascular disease (CVD) in patients with
normal renal function and chronic kidney disease. No data exists on the association between
adiponectin and CVD in renal transplant recipients (RTR).
Methods: Standard biochemistry, clinical data and adiponectin were collected from 137 RTR
recruited to the LANDMARK 2 study at baseline. The LANDMARK 2 study is an ongoing
randomized controlled study that compares the outcome of aggressive risk factor modification for
cardiovascular disease versus standard post-transplant care in renal transplant recipients with
impaired glucose tolerance or diabetes mellitus.
Results: Mean patient age was 53.4 ± 12 years and the median post-transplantation period was 5
(0.5-31.9) years. Mean serum adiponectin level was 12.3 ± 7.1 μg/mL. On univariate analysis,
adiponectin was positively associated with female gender (P = 0.01) and serum high-density
lipoprotein (HDL) concentration (P < 0.001), and inversely with body mass index (P = 0.009),
metabolic syndrome (P = 0.047), abnormal glucose tolerance (P = 0.01), C-reactive protein (P =
0.001) and serum triglyceride (P < 0.001). On stepwise multivariate analysis, adiponectin in males
was negatively correlated with combined baseline CVD (P = 0.03), waist-hip ratio (P = 0.003) and
glomerular filtration rate (P = 0.046), and positively with HDL (P < 0.001). In contrast, in females
adiponectin was inversely associated with C-reactive protein (P = 0.001) and serum triglyceride.
Conclusion: In conclusion, adiponectin is positively correlated with inflammation, dyslipidemia
and abnormal glucose tolerance in RTR. Furthermore, hypoadiponectinemia correlated with
increased baseline CVD in male RTR.
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Background
Cardiovascular disease (CVD) remains a major cause of
premature death in patients with chronic kidney disease
(CKD), including renal transplant recipients (RTR). RTR
in the age group of 35 to 44 year olds have up to a 10-fold
increase in cardiovascular death with nearly double that
rate within the ages of 55 to 64 [1]. Adiponectin is an
abundant multifunctional adipocyte derived protein with
anti-inflammatory, anti-atherogenic and insulin sensitiz-
ing activity [2]. Adiponectin has sequence homology to
the C1q family of complement proteins and circulates in
low, medium and high molecular weight forms. Clinical
data indicates that the high molecular weight form
strongly correlates with improved insulin sensitivity and
glucose tolerance than total adiponectin levels [3]. Adi-
ponectin levels have been shown to be lower in males,
obesity, insulin resistance, in patients with type 2 diabetes
mellitus, coronary artery disease and essential hyperten-
sion [4-7]. In contrast, adiponectin is elevated in kidney
disease including nephrotic syndrome [8], and particu-
larly in end-stage kidney disease, with levels up to three
times higher compared to the normal population [9]. The
rise in adiponectin with declining glomerular filtration
rate (GFR) is hypothesized to be secondary to diminished
renal elimination, though the exact role of the kidney in
the biodegradation and excretion of adiponectin remains
unclear. Recent observational studies have shown adi-
ponectin to be a novel risk marker of CVD in patients with
stage 1 to 5 CKD. These prospective studies have revealed
that low adiponectin levels to be predictive of the devel-
opment of new cardiovascular events in patients with
CKD, including the hemodialysis population [9-11]
While adiponectin has been shown to predict the devel-
opment of type 2 diabetes in renal transplant recipients
[12], there is yet to date any published data on the associ-
ation between adiponectin and CVD in RTR. We exam-
ined the relationship between cardiovascular disease and
adiponectin in RTR recruited to participate in the LAND-
MARK 2 study.
Materials and methods
Study Design and Population
The Longitudinal Assessment of Numerous Discrete Mod-
ifications of Atherosclerotic Risk Factors in Kidney disease
2 (LANDMARK 2) study is an ongoing 2 year, open label,
single centre randomized controlled trial. Conducted at
the Princess Alexandra Hospital in Brisbane, Australia it
compares aggressive risk factor modification for cardio-
vascular disease versus standard post-transplant care in
renal transplant recipients with impaired glucose toler-
ance or diabetes mellitus. Targets include aggressive cho-
lesterol and homocysteine reduction, blood pressure,
diabetic control and weight loss. Comparison will be
made to a control group with normal glucose tolerance
who will receive standard post-transplant care, as deter-
mined by a normal oral glucose tolerance test. Therefore,
our analysis included 102 patients with abnormal glucose
tolerance from the LANDMARK 2 study population and
35 matched RTR with normal glucose tolerance from the
substudy group which served as the control arm. All eligi-
ble patients provided informed consent to participate in
the study, which was approved by the Human Research
Ethics Committee of the University of Queensland and
Princess Alexandra Hospital. Impaired glucose tolerance
or diabetes was defined according to the World Health
Organization specifications [13].
Clinical Data
Demographic data were recorded, including age, sex, race,
cause of renal disease, duration of current transplant and
baseline cardiovascular disease. Assessment of cardiovas-
cular risk factors included any of the following before or
after transplantation: (1) Ischemic heart disease (acute
coronary syndrome requiring hospitalization, non-fatal
myocardial infarction, percutaneous coronary interven-
tion or coronary artery bypass graft surgery), (2) periph-
eral vascular disease (angioplasty, bypass or amputation),
(3) cerebrovascular event (transient ischemic attack or
stroke with neurologic deficit), (4) hypertension (previ-
ous or current use of antihypertensive agents or self
reported), (5) diabetes (previous or current use of oral
hypoglycemic agents or insulin) and (6) dyslipidemia
(previous or current use of lipid-lowering therapy or self
reported). Metabolic syndrome (MS) was defined accord-
ing to the National Cholesterol Education Panel Adult
Treatment Panel III (NCEP) criteria [14].
Clinical Measurements
Blood pressure (BP), height, weight, waist and hip circum-
ference were measured using standardized equipment.
Body mass index (BMI) and waist-hip ratio (WHR) were
determined. Central obesity was defined as waist circum-
ference ≥ 102 cm in men or 88 cm in women [15].
Biochemical Analysis
Blood specimens were collected after an 8-hour overnight
fast. Serum concentrations of creatinine, hemoglobin,
glucose, insulin, HbA1c, hsC-reactive protein, homo-
cysteine, adiponectin and lipids [total cholesterol, low
density lipoprotein (LDL), high density lipoprotein
(HDL), very low density lipoprotein (VLDL), Apolipopro-
tein a, Apolipoprotein b and triglycerides] were measured
using standard techniques. Homeostasis Model Assess-
ment of insulin resistance (HOMA) was calculated using
the standard formula = [Fasting insulin (μU/mL) × fasting
blood glucose (mmol/L) ÷ 22.5]. Serum adiponectin was
measures using the LINCO method (radioimmunoassay
technique-lower limit of detection 1 ng/mL; coefficient of
variance 6.6%).BMC Nephrology 2009, 10:29 http://www.biomedcentral.com/1471-2369/10/29
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Statistical Analysis
Statistical analysis was performed using standard statisti-
cal software (Stata 10 SE, StataCorp LP 2007). Results are
expressed in mean ± SD, median (interquartile range
[IQR]), or frequencies (%), depending on data distribu-
tion. A priori P < 0.05 was considered to be statistically sig-
nificant. Log transformation was performed for non-
parametric predictor variables. Univariate and multivari-
ate analysis was performed to determine which demo-
graphic, clinical and biochemical parameters were
associated with serum adiponectin. Variables with P < 0.1
on univariate analysis, which were not collinearly related,
were then entered into a backward elimination procedure
utilizing likelihood ratio until the most parsimonious
model was identified. Multivariate modeling was per-
formed stratified for gender because of published data
demonstrating associations between adiponectin to be
strongly gender dependent. Regression diagnostics,
including plots of residuals against the explanatory varia-
bles and against the fitted values, were carried out and
tests for normal distribution of the residuals were per-
formed. Variance inflation factor was checked as an index
of collinearity.
Results
Table 1 shows the baseline demographic characteristics of
all subjects from the LANDMARK 2 study. The mean
patient age was 53.4 years, with a larger proportion of
male participants and the median duration of kidney
transplantation was 5 (0.5 to 31.8) years. Fifty six (41.7%)
participants had type 2 diabetes while 46 (33.6%)
patients had impaired glucose tolerance. For the purpose
of analysis, the two groups were combined as the abnor-
mal glucose tolerance group. Most subjects (91%) had a
history of hypertension which was well controlled, with a
mean blood pressure of 133/77 mmHg. The mean GFR
was 51.8 mls/min/1.73 m2 and the majority of RTR had
stage 2 (57.7%) and 3 (29.2%) CKD. Serum adiponectin
was missing for 3 subjects. The mean adiponectin concen-
tration was 12.3 ± 7.1 μg/mL. After excluding subjects
with polycystic kidney disease, due to the unpredictability
in obtaining an accurate measurement of waist circumfer-
ence, 59 (43.1%) subjects had metabolic syndrome as
defined by the NCEP criteria. Combined cardiovascular
disease (acute coronary syndrome, myocardial infarction,
coronary artery bypass graft surgery, stroke and peripheral
vascular disease) was present at baseline in 35 subjects
(26%).
C-reactive protein (CRP) and random urinary protein cre-
atinine ratio were skewed and hence presented in tertiles.
On univariate analysis adiponectin levels were positively
correlated with female gender, HDL and Apolipoprotein a
(Table 2). Adiponectin levels correlated inversely with
BMI, WHR, abnormal glucose tolerance, metabolic syn-
drome, serum triglyceride, VLDL and CRP. There was no
significant correlation between adiponectin, fasting insu-
lin (P = 0.6) and HOMA scores (P = 0.9), although these
data were only available for 81 patients (59%). Further-
more, we failed to show any significant relationship
between serum adiponectin and measures of kidney func-
tion, including serum creatinine, CKD stage and GFR on
univariate analysis. In addition, we were unable to high-
light any significant association with the use of medica-
tions known to influence serum adiponectin levels,
including prednisolone, angiotensin converting enzyme
(ACE) inhibitors and angiotensin receptor blockers
(ARB). The majority of our patients received calcineurin
inhibitors (CNIs) as the primary immunosuppression
therapy. There was no significant association between
either a class effect of CNIs or individual treatment with
either cyclosporin or tacrolimus on serum adiponectin
levels.
Results of multivariate linear regression analysis, stratified
for gender are outlined in Table 3. In male RTR, adiponec-
tin levels were positively associated with HDL (β = 8.56, P
Table 1: Baseline characteristics of 137 subjects in the 
LANDMARK 2 study
Characteristics Value
Age (yrs) 53.4 ± 11.1
Sex M/F, n 85/52
Body mass index (kg/m2)2 8 . 1  ±  5 . 4
Abnormal glucose tolerance, n (%) 102 (75)
Duration of transplant (yrs) 7.8 (0.5-31.9)
Hypertension, n (%) 125 (91)
Systolic blood pressure (mmHg) 132.6 ± 15.2
Diastolic blood pressure (mmHg) 77.7 ± 10.5
CKD stage, n (%)
1 (>90 mls/min) 13 (9.5)
2 (60-90 mls/min) 79 (57.7)
3 (30-60 mls/min) 40 (29.2)
4 (15-30 mls/min) 5 (3.7)
MDRD Glomerular filtration rate 
(mls/min/1.73 m2)
51.8 ± 18.3
Fasting glucose (mmol/L)
-Abnormal glucose tolerance group 6.1 ± 2.2
-Normal glucose tolerance group 4.9 ± 4.5
Fasting cholesterol (mmol/L) 4.9 ± 1.1
Fasting triglyceride (mmol/L) 1.9 ± .9
C-reactive protein (mg/L) 8.0 ± 12.6
Adiponectin (μg/mL) 12.3 ± 7.1
Metabolic syndrome, n (%) 59 (43.1)
Combined baseline cardiovascular events 
(ACS, MI, CABG, stroke, PVD), n (%)
35 (26)
* Plus-minus values are mean ± SD. CKD-Chronic kidney disease; 
MDRD-Modification of Diet in Renal Disease; GFR-glomerular 
filtration rate; ACS-acute coronary syndrome; MI-myocardial 
infarction; CABG-coronary artery bypass graft surgery; PVD-
peripheral vascular diseaseBMC Nephrology 2009, 10:29 http://www.biomedcentral.com/1471-2369/10/29
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= 0.003). In contrast, the relationship between adiponec-
tin and both waist hip ratio (β = -18.3, P = 0.03) and GFR
were inverse, with the strongest correlation observed for
the relationship between adiponectin and WHR in the
regression model. There was a non-significant trend
towards an association between adiponectin and CRP in
male subjects. A major finding in our analysis was the sig-
nificant correlation between adiponectin and baseline
combined CVD in male RTR (β = -3.38, P = 0.03) with
stepwise multivariate linear regression analysis. In female
RTR, there was a highly significant negative relationship
between adiponectin, serum triglyceride and CRP.
Discussion
This study to our knowledge is the first to demonstrate a
significant link between lower adiponectin levels and
CVD in the renal transplant population. We demonstrated
that in male RTR with predominantly stage 2 and 3 CKD
there is a strong independent inverse association between
serum adiponectin levels and an increased prevalence of
cardiovascular disease. Our study also showed an inverse
correlation between waist-hip ratio and GFR with serum
adiponectin in males whilst in females adiponectin was
inversely associated with CRP and serum triglycerides.
Our findings related to CVD risk parallels similar results
from other studies in both the non-transplant population
with normal kidney function and CKD. Adiponectin lev-
els have been shown to vary inversely with GFR and CVD,
suggesting a potential protective role for adiponectin
against the development of cardiovascular events in
patients with kidney disease. This association has been
highlighted in several recent studies. Zoccali et al showed
that in their cohort of 227 hemodialysis patients, that
each 1 μg/mL increase in adiponectin concentration was
associated with a 3% risk reduction in new cardiovascular
events [9]. Analogous results have been observed in a
study by Becker et al, from the Mild to Moderate Kidney
study database in non-diabetic subjects with primarily
stage 3 to 4 CKD [10], where patients who developed new
cardiovascular events had significantly lower adiponectin
levels (odds ratio, 0.72; 95% CI 0.58 to 0.89; P = 0.002).
In a recent study, Iwashima et al showed that adiponectin
levels were significantly higher in patients with more
severe kidney impairment as assessed by CKD stage [11].
After dividing the patients into a high and low group
based upon gender-specific median values of adiponectin,
the low adiponectin group had a significantly shorter
Table 2: Variables associated with adiponectin on univariate 
linear regression analysis in the LANDMARK 2 population
Univariate Analysis
Variable β P 95% CI
Sex 3.24 0.01 7.71-5.71
Body mass index (kg/m2) -0.30 0.009 -0.53 to -0.08
Abnormal glucose tolerance -3.67 0.008 0.95-6.40
Metabolic syndrome -2.47 0.047 -4.91 to -0.03
Combined cardiovascular events -2.03 0.16 -4.84 to 0.79
Waist hip ratio (cm) -21.48 0.001 -33.06 to -9.90
Log fasting glucose (mmol/L) -4.55 0.04 -8.60 to -0.49
Log triglyceride (mmol/L) -6.10 <0.001 -8.63 to -3.56
Log HDL (mmol/L) 11.05 <0.001 7.23 to 14.88
VLDL (mmol/L) -5.99 0.001 -9.48 to -2.49
Apolipoprotein a (g/L) 10.93 <0.001 5.63 to 16.23
C-reactive protein (mg/L)
0.9-2 ref ref ref
2.1-4.7 -1.15 0.44 -4.07 to 1.77
4.8-84 -4.03 0.007 -6.95 to -1.11
Urinary PCR (mg/L)
5-14 ref ref ref
15-35 0.18 0.91 -3.10 to 3.47
36-1000 -2.27 0.15 -5.40 to 0.85
GFR (mls/min/1.73 m2) -0.45 0.18 -0.11 to 0.02
ACE inhibitor (mg/day) -2.12 0.1 -4.70 to 0.45
ARB (mg/day) 2.70 0.1 -0.51 to 5.90
*β-coefficient; Protein creatinine ratio (PCR)
Table 3: Variables associated with adiponectin on multivariate linear regression analysis in the LANDMARK 2 population
Variable Male Female
β P 95%CI β P 95% CI
Log HDL (mmol/L) 8.56 0.003 3.01-14.12
Log triglyceride (mmol/L) -6.29 0.007 -10.74 to -1.84
GFR (mls/min/1.73 m2) -0.07 0.046 -0.14 to -0.001
CRP (mg/L)
Tertile 1 ref ref ref ref ref
Tertile 2 -2.60 0.1 -5.70 to 0.51
Tertile 3 -3.26 0.07 -6.74 to 0.21 -6.56 0.007 -10.70 to -2.43
Waist hip ratio -18.30 0.003 -34.68 to -1.89
Combined CVD -3.38 0.03 -6.48 to -0.28
*ref = reference; β-coefficientBMC Nephrology 2009, 10:29 http://www.biomedcentral.com/1471-2369/10/29
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event-free survival compared to the higher group (<4.39
μg/ml in men, <6.84 μg/ml in women, P < 0.03). In con-
trast to the above findings, Menon et al, in their analysis
of 820 patients with a GFR range of between 13 and 55
mls/min from the MDRD (Modified Renal Diet) database
revealed a direct correlation between adiponectin and the
relative risk of cardiovascular mortality [16]. In multivari-
able adjusted Cox models, a 1 μg/ml increase in adiponec-
tin was associated with a 3% (hazard ratio 1.03; 95% CI
1.01 to 1.05; P = 0.02) elevated risk for all-cause and 6%
(hazard ratio 1.06; 95% CI 1.03 to 1.09; P = 0.001) higher
risk for cardiovascular mortality. The direct correlation
between adiponectin and CVD in the MDRD study may
be due to a residual confounding effect of reduced renal
function or processes accompanying CKD, but unadjusted
for reduced GFR. For example, the mean GFR and adi-
ponectin in the MDRD was 32 mls/min and 6 μmol/L
respectively, in comparison to 63 mls/min and 12 μmol/
L correspondingly in the study by Becker et al, highlight-
ing the strong association between adiponectin and GFR
[17].
Adiponectin has been shown to possess anti-inflamma-
tory and metabolic effects. Advantageous metabolic prop-
erties include improvement in glucose tolerance, higher
levels of HDL and reduction in triacylglycerol rich lipo-
proteins, a hallmark feature of obesity related dyslipi-
demia [18-20]. In our study, on multivariate analysis we
showed a positive association between adiponectin and
HDL in male RTR while the converse relationship with TG
was restricted to female subjects. We also demonstrated
that adiponectin varied inversely with CRP in our female
cohort of RTR (P = 0.007), whilst there was a non-statitis-
tically similar trend between CRP and adiponectin in our
male patients (P = 0.07). In multiple studies, adiponectin
has been shown to be inversely associated with markers of
inflammation including CRP [21-23]. Higher adiponectin
levels in CKD may represent a compensatory process to
the inflammatory milieu in the kidney disease. Adiponec-
tin has also been shown to exhibit anti-inflammatory
activity in atherosclerotic experimental models [24,25]. In
addition, adiponectin ameliorates VSMC proliferation by
inhibition of mitogen-activated protein kinase, increases
production of nitric oxide and tissue inhibitor of metallo-
proteinase-1, resulting in vasodilatation and decrease in
plaque rupture respectively [26-28].
Our study has several limitations. Firstly, as the findings
from this study are derived from observational data, a
cause and effect inference cannot be made between the
study variables. Furthermore, while our study size was
small, it is similar in number to previously cited studies in
CKD patients that assessed the association between adi-
ponectin and CVD and with similar outcome findings. In
addition, the smaller number of female participants may
obscure a potentially significant interaction between adi-
ponectin and CVD in this group, though we believe the
likelihood of a type 2 error is low and the results are sta-
tistically and biologically genuine. In addition, the HMW
isoform was not measured as current assays for the HMW
form are not standardized and unreliable.
The strengths of our study include the statistical adjust-
ment performed for other factors associated with an
increased risk of CVD such as abnormal glucose tolerance,
dyslipidemia, hypertension and inflammation. We also
performed stratified regression analyses according to gen-
der based upon previous published studies that con-
firmed an association between adiponectin and
cardiovascular events in male subjects, a higher incidence
of CVD in men compared to women and a significant dif-
ference in adiponectin between the genders on univariate
analysis.
Our findings suggest that higher adiponectin levels may
be protective against the development of CVD in male
renal transplant recipients. The observed relationship
between hypoadiponectinemia and increased CVD in
male RTR may be explained by several factors. As adi-
ponectin is positively correlated with HDL, low HDL lev-
els in hypoadiponectenemia may partly account for the
increased risk of CVD. The smaller number of female
patients may have obscured a similar finding in this
group. There exists a biological rationale for increasing
adiponectin levels in an attempt to improve outcomes
from atherosclerotic disease in this population. Several
medications, including ACE inhibitors, ARB and thiazoli-
dinediones have been shown to increase adiponectin lev-
els in patients with normal kidney function and CKD [29-
31]. However, there have been no published studies on
the effect of increasing adiponectin levels and subsequent
cardiovascular outcomes. In conclusion, it is important
that future studies continue to delineate the biological rel-
evance of adiponectin either as a biomarker of vascular
disease or potential therapeutic agent in improving cardi-
ovascular outcomes in RTR and other populations with
high cardiovascular risk.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MK Statistical analysis of paper, first author, reviewed sub-
jects in clinic and collection of clinical data.
KA Assisted in design of study, analysis of data, reviewed
subjects in clinic and collection of clinical data.
HC Statistical analysis, drafting and revision of paper for
publication.BMC Nephrology 2009, 10:29 http://www.biomedcentral.com/1471-2369/10/29
Page 6 of 7
(page number not for citation purposes)
SC Assisted in drafting of manuscript and revision of
paper for publication.
DM Assisted in drafting of manuscript and revision of
paper for publication.
DJ Co-investigator, design of study, drafting and revision
of paper for publication.
JP Co-investigator, design of study, drafting and revision
of paper for publication.
NI Primary investigator, design of study, drafting and revi-
sion of paper for publication.
All authors read and approved the final manuscript.
Acknowledgements
Rachael Hale, RN, for her clinical and organizational support. All the partic-
ipants involved in the study.
This study was funded by the Centre for Clinical Research and Excellence, 
National Health and Medical Research Council.
References
1. Pham PT, Pham PC, Donovitch GM: Cardiovascular disease post-
transplant.  Semin Nephrol 2007, 27(4):430-44.
2. Rabin KR, Kamari Y, Avni I, Grossman E, Sharabi Y: Adiponectin:
linking the metabolic syndrome to its cardiovascular conse-
quences.  Expert Rev Cardiovasc Ther 2005, 3(3):465-471.
3. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H,
Imai Y, Nagai R, Kadowaki T: Measurement of the high-molecu-
lar weight form of adiponectin in plasma is useful for the pre-
diction of insulin resistance and metabolic syndrome.
Diabetes Care 2006, 29(6):1357-1362.
4. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB: Adi-
ponectin--a key adipokine in the metabolic syndrome.  Diabe-
tes Obes Metab 2006, 8(3):264-280.
5. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y,
Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S,
Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Naka-
mura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentra-
tions of a novel, adipose-specific protein, adiponectin, in type
2 diabetic patients.  Arterioscler Thromb Vasc Biol 2000,
20(6):1595-1599.
6. Iwashima Y, Katsuya T, Ishikawa K, Kida I, Ohishi M, Horio T, Ouchi
N, Ohashi K, Kihara S, Funahashi T, Rakugi H, Ogihara T: Associa-
tion of hypoadiponectinemia with smoking habit in men.
Hypertension 2005, 45(6):1094-1100.
7. Dzieliñska Z, Januszewicz A, Wiecek A, Demkow M, Makowiecka-
Cies ´ la M, Prejbisz A, Kadziela J, Mielniczuk R, Florczak E, Janas J,
Januszewicz M, Ruzyłło W: Decreased plasma concentration of
a novel anti-inflammatory protein adiponectin in hyperten-
sive men with coronary artery disease.  Thromb Res 2003,
110(5-6):365-369.
8. Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S,
Catalano F, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y:
Adiponectin is markedly increased in patients with neph-
rotic syndrome and is related to metabolic risk factors.  Kid-
ney Int Suppl 2003:S98-102.
9. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo
S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi
M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa
Y: Adiponectin, metabolic risk factors, and cardiovascular
events among patients with end-stage renal disease.  J Am Soc
Nephrol 2002, 13(1):134-141.
10. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E,
Fliser D, MMKD Study Group: Renal insulin resistance syn-
drome, adiponectin and cardiovascular events in patients
with kidney disease: the mild and moderate kidney disease
study.  J Am Soc Nephrol 2005, 16(4):1091-1098.
1 1 . I w a s h i m a  Y ,  H o r i o  T ,  K u m a d a  M ,  S u z u k i  Y ,  K i h a r a  S ,  R a k u g i  H ,
Kawano Y, Funahashi T, Ogihara T: Adiponectin and renal func-
tion, and implication as a risk of cardiovascular disease.  Am J
Cardiol 2006, 98(12):1603-1608.
12. Bayes B, Lauzurica R, Granada ML, Serra A, Bonet J, Fontsere N, Sali-
nas I, Romero R: Adiponectin and risk of new-onset diabetes
mellitus after kidney transplantation.  Transplantation 2004,
78(1):26-30.
13. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Compli-
cations: Report of a WHO Consultation. Part 1: Diagnosis and Classification
of Diabetes Mellitus Geneva, World Health Organization; 1999. 
14. Third Report of the National Cholesterol Education Pro-
gram (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III) final report.  Circulation 2002,
106(25):3143-3421.
15. Clinical Guidelines on the Identification, Evaluation, and
Treatment of Overweight and Obesity in Adults--The Evi-
dence Report. National Institutes of Health.  Obes Res 1998,
6(Suppl 2):51S-209S.
16. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, Pereira
AA, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ: Adiponec-
tin and mortality in patients with chronic kidney disease.  J
Am Soc Nephrol 2006, 17(9):2599-2606.
17. Zoccali C, Mallamaci F: Adiponectin and renal disease progres-
sion: another epidemiologic conundrum?  Kidney Int 2007,
71(12):1195-1197.
18. Fu Y, Luo N, Klein RL, Garvey WT: Adiponectin promotes adi-
pocyte differentiation, insulin sensitivity, and lipid accumula-
tion.  J Lipid Res 2005, 46:1369-1379.
19. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ,
Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE: Relationship of adi-
ponectin to body fat distribution, insulin sensitivity and
plasma lipoproteins: evidence for independent roles of age
and sex.  Diabetologia 2003, 46(4):459-469.
20. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB: Circulating adi-
ponectin levels are associated with better glycemic control,
more favorable lipid profile, and reduced inflammation in
women with type 2 diabetes.  J Clin Endocrinol Metab 2005,
90(8):4542-4548.
21. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M,
Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda
N, Kobayashi H, Hiraoka H, Matsuzawa Y: Reciprocal association
of C-reactive protein with adiponectin in blood stream and
adipose tissue.  Circulation 2003, 107:671-674.
22. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G: Adi-
ponectin expression from human adipose tissue: relation to
obesity, insulin resistance, and tumor necrosis factor-alpha
expression.  Diabetes 2003, 52:1779-1785.
23. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Mat-
suzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay
RS: Inflammatory markers, adiponectin, and risk of type 2
diabetes in the Pima Indian.  Diabetes Care 2003, 26:1745-1751.
24. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta
K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T,
Yamashita S, Funahashi T, Matsuzawa Y: Adiponectin, an adi-
pocyte-derived plasma protein, inhibits endothelial NF-kap-
paB signaling through a cAMP-dependent pathway.  Circulation
2000, 102:1296-1301.
25. Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, Summer
RS, Kihara S, Walsh K: Adiponectin modulates inflammatory
reactions via calreticulin receptor-dependent clearance of
early apoptotic bodies.  J Clin Invest 2007, 117:375-386.
26. Arita Y, Kihara S, Ouchi N, et al.: Adipocyte-derived plasma pro-
tein, adiponectin, acts as a platelet-derived growth-factor-
BB-binding protein and regulates growth factor-induced
common post-receptor signal in vascular smooth muscle
cell.  Circulation 2002, 105:2893-2898.
27. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ: Adi-
ponectin stimulates nitric oxide production in vascular
endothelial cells.  J Biol Chem 2003, 278:45021-45026.
28. Kumada M, Kihara S, Ouchi N, et al.:  Adiponectin specifically
increased tissue inhibitor of metalloproteinase-1 throughPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Nephrology 2009, 10:29 http://www.biomedcentral.com/1471-2369/10/29
Page 7 of 7
(page number not for citation purposes)
interleukin-10 expression in human macrophages.  Circulation
2004, 109:2046-2049.
29. Koh K, Quon M, Han S, et al.: Vascular and metabolic effects of
combined therapy with ramipril and simvastatin in patients
with type 2 diabetes.  Hypertension 2005, 45:1088-1093.
30. Yenicesu M, Yilmaz MI, Caglar K, et al.: Blockade of the renin-angi-
otensin system increases plasma adiponectin concentration
in type 2 diabetic patients with proteinuria.  Nephron Clin Pract
2005, 99:115-121.
31. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha
M, Olefsky JM: The effect of thiazolidinedione on plasma adi-
ponectin levels in normal, obese, and type 2 diabetic sub-
jects.  Diabetes 2002, 51:2968-2974.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2369/10/29/pre
pub